Jocelyne Piret1, Guy Boivin. 1. Research Center in Infectious Diseases, CHU of Quebec and Laval University, Quebec City, Quebec, Canada.
Abstract
PURPOSE OF REVIEW: Aciclovir (ACV) is the first-line drug for the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Long-term administration of ACV for the treatment of severe infections in immunocompromised patients can lead to the development of drug resistance. Furthermore, the emergence of isolates resistant to ACV is increasingly recognized in immunocompetent individuals with herpetic keratitis. This review describes the mechanisms involved in drug resistance for HSV and VZV, the laboratory diagnosis and management of patients with infections refractory to ACV therapy. RECENT FINDINGS: Genotypic testing is more frequently performed for the diagnosis of infections caused by drug-resistant HSV or VZV isolates. Molecular biology-based systems for the generation of recombinant viruses have been developed to link unknown mutations with their drug phenotypes. Fast and sensitive methods based on next-generation sequencing will improve the detection of heterogeneous viral populations of drug-resistant viruses and their temporal changes during antiviral therapy, which could allow better patient management. Novel promising compounds acting on targets that differ from the viral DNA polymerase are under clinical development. SUMMARY: Antiviral drug resistance monitoring for HSV and VZV is required for a rational use of antiviral therapy in high-risk populations.
PURPOSE OF REVIEW: Aciclovir (ACV) is the first-line drug for the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Long-term administration of ACV for the treatment of severe infections in immunocompromised patients can lead to the development of drug resistance. Furthermore, the emergence of isolates resistant to ACV is increasingly recognized in immunocompetent individuals with herpetic keratitis. This review describes the mechanisms involved in drug resistance for HSV and VZV, the laboratory diagnosis and management of patients with infections refractory to ACV therapy. RECENT FINDINGS: Genotypic testing is more frequently performed for the diagnosis of infections caused by drug-resistant HSV or VZV isolates. Molecular biology-based systems for the generation of recombinant viruses have been developed to link unknown mutations with their drug phenotypes. Fast and sensitive methods based on next-generation sequencing will improve the detection of heterogeneous viral populations of drug-resistant viruses and their temporal changes during antiviral therapy, which could allow better patient management. Novel promising compounds acting on targets that differ from the viral DNA polymerase are under clinical development. SUMMARY: Antiviral drug resistance monitoring for HSV and VZV is required for a rational use of antiviral therapy in high-risk populations.
Authors: Ella J Ariza-Heredia; Roy F Chemaly; Lokesh R Shahani; Ying Jang; Richard E Champlin; Victor E Mulanovich Journal: Transpl Int Date: 2018-03-13 Impact factor: 3.782
Authors: Debra C Quenelle; Alexander Birkmann; Thomas Goldner; Tamara Pfaff; Holger Zimmermann; Susanne Bonsmann; Deborah J Collins; Terri L Rice; Mark N Prichard Journal: Antiviral Res Date: 2017-11-04 Impact factor: 5.970
Authors: Amanda M Casto; Sean C Stout; Rangaraj Selvarangan; Alexandra F Freeman; Brandon D Newell; Erin D Stahl; Atif A Ahmed; Alexander L Greninger; Dwight E Yin Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Matthew R Pennington; Ian E H Voorhees; Heather M Callaway; Shannon D Dehghanpir; Joel D Baines; Colin R Parrish; Gerlinde R Van de Walle Journal: J Virol Date: 2018-09-26 Impact factor: 5.103
Authors: Iulia A Neagu; Jason Olejarz; Mark Freeman; Daniel I S Rosenbloom; Martin A Nowak; Alison L Hill Journal: PLoS Comput Biol Date: 2018-02-15 Impact factor: 4.475